Fact check
“This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for pralidoxime chloride solution, 600 mg/2 mL (300 mg/mL), if all other legal and regulatory requirements are met.”
Reasoning
The claim concerns a regulatory determination by the FDA regarding approval of ANDAs for a specific formulation of pralidoxime chloride. Without any provided documents, there is no way to verify whether such a determination exists or its conditions.
On confidence: No evidence was supplied to confirm or refute the claim.
Important context
Verification would require official FDA announcements, Federal Register notices, or other authoritative regulatory documents referencing this specific determination.
Evidence
No retrievable evidence was found; the verdict rests on the reporting itself and is marked accordingly.
Limitations
The assessment is based solely on the absence of supplied evidence; no external sources were consulted.
- Last verified:
- Oct 6, 2026, 4:15 AM CDT
- Pipeline:
- 2.1.0
- Claim type:
- Factual
Where this claim appeared
Determination PRALIDOXIME CHLORIDE (Autoinjector) (Pralidoxime Chloride) Solution, 600 Milligrams/2 Milliliters (300 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or EffectivenessFederal Register · Drug Administration, Human Services Department, Food, Health